Credit: Insilico Medicine
Tuesday, October 25, Baltimore, MD – Insilico Medicine today announced that it will present its recent advances in applying deep learning techniques to drug discovery and repurposing at the Strategic Partnerships in Drug Repurposing conference in Boston taking place at the Wyndham Boston Beacon Hill 27-28th of October. The CEO of Insilico Medicine, Alex Zhavoronkov, Ph.D. will give a talk titled "Deep Learning for Drug Repurposing".
"We are very happy to be invited to present our research on deep-learned predictors of therapeutic use and adverse effects of the molecules trained on transcriptional response data and large data sets of molecular fingerprints. Many approved drugs and drugs that are currently in the pipelines of major pharmaceutical companies may be even more effective in conditions unrelated to the primary indications. We developed rather sophisticated pipelines to identify these alternative indications and can be used in precision medicine and even personalized drug discovery applications", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.
Advances in artificial intelligence are quickly propagating into areas, where large data sets are available for training and the pharmaceutical industry in no exception. Earlier this year Insilico Medicine published several seminal papers describing proofs of concept of application of deep learning techniques to drug discovery (Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data in Molecular Pharmaceutics), to biomarker development (Deep biomarkers of human aging: Application of deep neural networks to biomarker development in Aging, and to predicting the differentiation state of cells and tissues by developing a resource called Embryonic.AI in collaboration with Biotime. These concepts have been significantly expanded and applied to massive public and private data sets. The company presented a study on issues with population-specificity of deep blood biochemistry biomarkers as well as new machine learning techniques for geroprotector discovery at its annual International Aging Research for Drug Discovery Forum in Basel, Switzerland in September.
###
About Strategic Partnerships in Drug Repurposing
The Strategic Partnerships for Drug Repurposing Forum is organized by a conference conglomerate ExL Events. The conference is focused on the latest advances in drug repurposing, repositioning and rescue. Delegates learn about the different resources available to them, including public-private partnerships, foundations, patient advocacy groups, universities and other funding partners.The conference helps identify therapeutic areas or disease states that need drugs, and enable them to adopt and customize a plan for their own business models.
The conference program is available at: http://exlevents.com/strategic-partnerships-drug-repurposing-forum/
About Insilico Medicine, Inc
Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia and Poland hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharma.AI division the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8
Media Contact
Qingsong Zhu
[email protected]
410-710-9674
@InSilicoMeds
http://www.insilicomedicine.com
